11/01/2019 13:00:00

ShiftPixy, Inc. Reports Fiscal 2019 First Quarter Results

IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- ShiftPixy, Inc. (NASDAQ: PIXY), a developing, proprietary next-gen technology platform for workforce engagement and management, today announced operating results for the three months ended November 30, 2018 (“2019 First Quarter”).

2019 First Quarter Highlights

  • Gross billings grew 77% to $70.9 million, compared to $40.2 million for the fiscal 2018 first quarter; gross billings for the quarter decreased 3.4% sequentially from $73.4 million in the prior quarter.
  • Revenues increased 62% to $10.5 million for the quarter, compared to $6.5 million for the first quarter of fiscal 2018.
  • Worksite employees increased by 3,520 to an average of 8,990 compared to an average of 5,470 for the quarter ended November 30, 2017; the number of employees at the end of the quarter also represented a sequential increase of approximately 740 over the number of employees at the end of the fourth quarter of fiscal 2018.
  • Gross profit for the quarter was $3.4 million versus $1.2 million in the prior year period, and net loss per share was 7 cents during the quarter, versus a net loss of 12 cents the prior year period.

"It’s an exciting time for ShiftPixy and it's gratifying to see the rapid adoption of our platform driving strong growth in both our client base and our number of worksite employees,” stated Chief Executive Officer, Scott Absher. “We are pleased with the pace of our growth and anticipate that our rapidly developing technology platform will further enhance our service offerings and better enable us to meet the needs of our assigned workforce and clients as we endeavor to create value for our shareholders.”


ShiftPixy will host a webcast at 8:30 a.m. Eastern Time on Friday, January 11, 2019, to discuss financial results for its 2019 fiscal first quarter. Investors can access the webcast through the ShiftPixy website at https://ir.shiftpixy.com.

About ShiftPixy

ShiftPixy is a disruptive human capital management (HCM) services provider, revolutionizing employment in the Gig Economy by delivering a next-gen platform for workforce management that helps businesses with shift-based employees navigate regulatory mandates, minimize administrative burdens and better connect with a ready-for-hire workforce. With expertise rooted in management’s nearly 25 years of workers’ compensation and compliance programs experience, ShiftPixy adds a needed layer for addressing compliance and continued demands for equitable employment practices in the growing Gig Economy. ShiftPixy’s complete HCM ecosystem is designed to manage regulatory requirements and compliance in such required areas as paid time off (PTO) laws, insurance and workers’ compensation, minimum wage increases, and the Affordable Care Act (ACA) compliance.

ShiftPixy Cautionary Statement

The information provided in this release includes forward-looking statements, the achievement or success of which involves risks, uncertainties, and assumptions. Although such forward-looking statements are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate. If any of the risks or uncertainties, including those set forth below, materialize or if any of the assumptions proves incorrect, the results of ShiftPixy, Inc., could differ materially from the results expressed or implied by the forward-looking statements we make.  The risks and uncertainties include, but are not limited to, risks associated with the nature of our business model; our ability to execute the Company's vision and growth strategy; our ability to attract and retain clients; our ability to assess and manage risks; changes in the law that affect our business and our ability to respond to such changes and incorporate them into our business model, as necessary; our ability to insure against and otherwise effectively manage risks that affect our business; competition; reliance on third-party systems and software; our ability to protect and maintain our intellectual property; and general developments in the economy and financial markets.  Statements made in connection with any guidance may refer to financial statements that have not been reviewed or audited.  The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws.  The information in this press release shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.  Further information on these and other factors that could affect the financial results of ShiftPixy, Inc., is included in the filings on Forms 1-A and 10-Q and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the "SEC Filings" subsection of the "Investor Information" section of our website at https://ir.shiftpixy.com/financial-information/sec-filings.

Consistent with the SEC’s April 2013 guidance on using social media outlets like Facebook and Twitter to make corporate disclosures and announce key information in compliance with Regulation FD, ShiftPixy is alerting investors and other members of the general public that ShiftPixy will provide updates on operations and progress required to be disclosed under Regulation FD through its social media on Facebook, Twitter, LinkedIn and YouTube. Investors, potential investors, shareholders and individuals interested in our Company are encouraged to keep informed by following us on Facebook, Twitter, LinkedIn and YouTube.



Clark Wilson






ShiftPixy, Inc.

Condensed Consolidated Balance Sheets 


November 30,



August 31,








Current assets



 $  227,454  $1,649,783 

Accounts receivable

  129,452   110,931 

Unbilled accounts receivable


 4,759,141   6,192,631 

Deposit – workers’ compensation

  1,923,465   1,672,097 

Prepaid expenses

  378,525   563,002 

Other current assets

  351,555    258,901 

Total current assets

  7,769,592   10,447,345 

Fixed assets, net

  3,337,861   3,032,325 

Deposits – workers’ compensation

  2,841,882   2,201,556 

Deposits and other assets

  94,375   120,606 

Total assets

 $  14,043,710   $15,801,832 







Current liabilities


Accounts payable

 $ 1,486,581  $1,246,461 

Payroll related liabilities

  7,488,262   9,476,641 

Convertible note, net

  6,309,104   7,156,515 

Accrued workers’ compensation costs

  634,697   305,217 

Registration rights penalties accrual (Note 9)

  3,500,000   3,500,000 

Other current liabilities

  1,230,418   1,955,921 

Total current liabilities

  20,649,062   23,640,755 


Non-current liabilities


Accrued workers’ compensation costs

  1,639,900   900,978 

Total liabilities

  22,288,962   24,541,733 



Commitments and contingencies




Stockholders' deficit


Preferred stock, 50,000,000 authorized shares; $0.0001 par value; no shares issued and outstanding

  -   - 

Common stock, 750,000,000 authorized shares; $0.0001 par value;


and 28,851,787 shares issued and outstanding, respectively

  2,983   2,886 

Additional paid-in capital

  19,728,657   17,233,919 

Accumulated deficit

  (27,976,892)  (25,976,706)

Total stockholders' deficit

  (8,245,252)  (8,739,901)

Total liabilities and stockholders’ deficit

 $  14,043,710  $15,801,832 


ShiftPixy Inc.

Condensed Consolidated Statements of Operations 



For the Three Months

Ended November 30,






Revenues (gross billings of $70.9 million and $40.2 million less worksite employee payroll cost of $60.4 million and $33.7 million, respectively)

 $10,519,990   $6,511,919 

Cost of revenue

  7,134,168     5,266,403 

Gross profit

  3,385,822    1,245,516 

Operating expenses:


Salaries, wages and payroll taxes

  1,794,965    1,180,489 

Stock-based compensation - general and administrative

  77,222    70,296 


  553,216    271,630 

Professional fees

  624,045    492,455 

Software development

  310,000    1,900,000 

Depreciation and amortization

  187,723    17,695 

General and administrative

  1,127,915    654,168 

Total operating expenses

  4,675,086    4,586,733 

Operating Loss

  (1,289,264)   (3,341,217)

 Other Expense


Interest expense

  (710,922    - 

Net Loss

  $(2,000,186  $ (3,341,217

Net loss per common share


Basic and diluted

 $(0.07  $(0.12

Weighted average number of common shares


Basic and diluted

  28,921,300    26,767,850 



Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Jun
Hvad er det for noget eklatant ævl.Hvis man sammenholder de store fondes indtog på det danske aktiem..
13 Jun
Jeg er meget imponeret over Jyske bank og i særdeleshed analytikkeren Janne Vincent Kjær. Kunne rest..
09 Jun
Ok ja. Og i Schweiz betaler hverken dem der arbejder eller firmaer noget særligt i skat og alligevel..
12 Jun
er i dag ude med en dødsdoms artikel omkring Pandora. Artiklen er skrevet af en velanset analytiker,..
12 Jun
Novo Nordisk aktien er d.d. steget med 120 kr. siden d. 25. nov. 2016. Dvs. fra 226 til 346 kr. 💪 ..
10 Jun
https://clinicaltrials.gov/ct2/show/study/NCT03979365 Bliver også spændene, at se om Envarsus sna..
15 Jun
Udover den samme analyse blev offentligjort for snart 3 uger siden er det da glimrende at man igen, ..
13 Jun
Nå du mener som IKEA, KIA, Hyundai, Harald Nyborg, Jysk og alle de andre hvor ingen vil handle..;)Må..
13 Jun
Kildevand på flaske ligeledes. Forbyd det. Kildevand, der fragtes fra Frankrig og  Italien til Danma..
12 Jun
Uden at have noget kendskab til Per Hansen artiklen, så kan jeg med sikkerhed sige, at din kommentar..


EuroInvestor: In Focus


EuroInvestor: In Focus


EuroInvestor: In Focus

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
16 June 2019 04:26:47
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB3 - 2019-06-16 05:26:47 - 2019-06-16 04:26:47 - 1000 - Website: OKAY